Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy.

Inoue K, Suzuki E, Takahashi T, Yamamoto Y, Yazawa R, Takahashi Y, Imai K, Miyakawa K, Inoue Y, Tsuji D, Hayashi H, Itoh K.

Epilepsy Res. 2014 Aug;108(6):1046-51. doi: 10.1016/j.eplepsyres.2014.04.008. Epub 2014 May 14.

PMID:
24888247
2.

Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.

Inoue K, Takahashi T, Yamamoto Y, Suzuki E, Takahashi Y, Imai K, Inoue Y, Hirai K, Tsuji D, Itoh K.

Seizure. 2015 Dec;33:76-80. doi: 10.1016/j.seizure.2015.10.015. Epub 2015 Nov 6.

3.

Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia.

Yagi M, Nakamura T, Okizuka Y, Oyazato Y, Kawasaki Y, Tsuneishi S, Sakaeda T, Matsuo M, Okumura K, Okamura N.

Pediatr Int. 2010 Oct;52(5):744-8. doi: 10.1111/j.1442-200X.2010.03157.x.

PMID:
20456087
4.

Perioperative exacerbation of valproic acid-associated hyperammonemia: a clinical and genetic analysis.

Bezinover D, Postula M, Donahue K, Bentzen B, McInerney J, Janicki PK.

Anesth Analg. 2011 Oct;113(4):858-61. doi: 10.1213/ANE.0b013e318228a001. Epub 2011 Aug 4.

PMID:
21821508
5.

Risk factors for hyperammonemia in pediatric patients with epilepsy.

Yamamoto Y, Takahashi Y, Imai K, Mishima N, Yazawa R, Inoue K, Itoh K, Kagawa Y, Inoue Y.

Epilepsia. 2013 Jun;54(6):983-9. doi: 10.1111/epi.12125. Epub 2013 Feb 14.

6.

Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients.

Yamamoto Y, Takahashi Y, Suzuki E, Mishima N, Inoue K, Itoh K, Kagawa Y, Inoue Y.

Epilepsy Res. 2012 Sep;101(3):202-9. doi: 10.1016/j.eplepsyres.2012.04.001. Epub 2012 Apr 28.

PMID:
22542569
7.

Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.

Tseng YL, Huang CR, Lin CH, Lu YT, Lu CH, Chen NC, Chang CC, Chang WN, Chuang YC.

Medicine (Baltimore). 2014 Sep;93(11):e66. doi: 10.1097/MD.0000000000000066.

8.

Carbamoylphosphate synthetase 1 (CPS1) deficiency: clinical, biochemical, and molecular characterization in Malaysian patients.

Ali EZ, Khalid MK, Yunus ZM, Yakob Y, Chin CB, Abd Latif K, Hock NL.

Eur J Pediatr. 2016 Mar;175(3):339-46. doi: 10.1007/s00431-015-2644-z. Epub 2015 Oct 6.

PMID:
26440671
9.

Cognitive side effects of valproic acid-induced hyperammonemia in children with epilepsy.

Nicolai J, Aldenkamp AP, Huizenga JR, Teune LK, Brouwer OF.

J Clin Psychopharmacol. 2007 Apr;27(2):221-4. No abstract available.

PMID:
17414255
10.

Changing incidence of hyperammonemia in Japan from 2006 to 2013: expansion of new antiepileptic drugs reduces the risk of hyperammonemia.

Yamamoto Y, Takahashi Y, Imai K, Mishima N, Kagawa Y, Inoue Y.

Eur J Clin Pharmacol. 2015 Dec;71(12):1517-24. doi: 10.1007/s00228-015-1939-3. Epub 2015 Sep 22.

PMID:
26391520
11.

Correlation between plasma ammonia level and serum trough concentration of free valproic acid in patients with epilepsy.

Itoh H, Suzuki Y, Fujisaki K, Sato Y, Takeyama M.

Biol Pharm Bull. 2012;35(6):971-4.

12.

[Hyperammonemia secondary to the use of valproic acid: case report].

Turcato Mde F, Fernandes RM, Wichert-Ana L, Funayama CA.

Arq Neuropsiquiatr. 2005 Jun;63(2A):364-6. Portuguese.

13.

Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients.

Inoue K, Suzuki E, Yazawa R, Yamamoto Y, Takahashi T, Takahashi Y, Imai K, Koyama S, Inoue Y, Tsuji D, Hayashi H, Itoh K.

Ther Drug Monit. 2014 Jun;36(3):406-9. doi: 10.1097/FTD.0000000000000012.

PMID:
24365988
14.

The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.

Hamed SA, Abdella MM.

Epilepsy Res. 2009 Sep;86(1):32-41. doi: 10.1016/j.eplepsyres.2009.04.002. Epub 2009 May 14.

PMID:
19446440
15.

Valproic acid-induced hyperammonemia: a case report.

McCall M, Bourgeois JA.

J Clin Psychopharmacol. 2004 Oct;24(5):521-6.

PMID:
15349008
16.

Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs.

Verrotti A, Greco R, Morgese G, Chiarelli F.

Int J Clin Lab Res. 1999;29(1):36-40.

PMID:
10356662
17.

A novel UPLC-MS/MS based method to determine the activity of N-acetylglutamate synthase in liver tissue.

Dercksen M, Duran M, IJlst L, Kulik W, Ruiter JP, van Cruchten A, Tuchman M, Wanders RJ.

Mol Genet Metab. 2016 Dec;119(4):307-310. doi: 10.1016/j.ymgme.2016.10.004. Epub 2016 Oct 13.

PMID:
27771289
18.

Valproate-induced hyperammonemia.

Batshaw ML, Brusilow SW.

Ann Neurol. 1982 Mar;11(3):319-21.

PMID:
6807193
19.

New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA.

Aires CC, van Cruchten A, Ijlst L, de Almeida IT, Duran M, Wanders RJ, Silva MF.

J Hepatol. 2011 Aug;55(2):426-34. doi: 10.1016/j.jhep.2010.11.031. Epub 2010 Dec 13.

PMID:
21147182
20.

Valproic acid-induced hyperammonemia and thrombocytopenia in an elderly woman.

Mallet L, Babin S, Morais JA.

Ann Pharmacother. 2004 Oct;38(10):1643-7. Epub 2004 Aug 17.

PMID:
15316109

Supplemental Content

Support Center